Literature DB >> 15337487

The economics of cancer care in the UK.

Nick Bosanquet1, Karol Sikora.   

Abstract

Cancer care accounts for an increasing proportion of global spending on healthcare, driven by an increased incidence caused by ageing populations, greater frequency from better treatments, and changes in care that have made cancer a chronic, controllable illness. The cost of cancer care has three components: direct and easily determined clinical costs (ie, medical costs); extra financial requirement of living with disease for the patient and their family (ie, morbidity costs); and loss of income from the premature death (ie, mortality costs). Effective planning of cancer services needs detailed consideration of the economics of care delivery-an area of research that has so far been lacking outside the USA. Here, we review the literature and attempt to answer key questions on the economics of cancer care, including probable changes in disease burden over the next 20 years, changes in the way costs will be distributed between carers and delivery services, changing patterns of service delivery, and the direct contribution patients will make to treatment costs in terms of co-payments and escalating costs of comorbidity in elderly populations.

Entities:  

Mesh:

Year:  2004        PMID: 15337487     DOI: 10.1016/S1470-2045(04)01569-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  19 in total

1.  Cancer care urgently needs a real reform engine.

Authors:  Nick Bosanquet; Karol Sikora
Journal:  J R Soc Med       Date:  2009-01       Impact factor: 5.344

Review 2.  The perceived cancer-related financial hardship among patients and their families: a systematic review.

Authors:  Meram Azzani; April Camilla Roslani; Tin Tin Su
Journal:  Support Care Cancer       Date:  2014-10-22       Impact factor: 3.603

3.  An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer.

Authors:  Tomas Philipson; Michael Eber; Darius N Lakdawalla; Mitra Corral; Rena Conti; Dana P Goldman
Journal:  Health Aff (Millwood)       Date:  2012-04       Impact factor: 6.301

4.  The economic consequences of breast cancer adjuvant hormonal treatments.

Authors:  Liliana E Pezzin; Mallory B O'Niel; Ann B Nattinger
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

5.  The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study.

Authors:  M J Proctor; D Talwar; S M Balmar; D S J O'Reilly; A K Foulis; P G Horgan; D S Morrison; D C McMillan
Journal:  Br J Cancer       Date:  2010-08-17       Impact factor: 7.640

6.  The emerging low-dose therapy for advanced cancers.

Authors:  Jahangir Satti
Journal:  Dose Response       Date:  2009-03-24       Impact factor: 2.658

7.  The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer.

Authors:  Colin H Richards; Campbell S D Roxburgh; Mark T MacMillan; Sanad Isswiasi; Ewen G Robertson; Graeme K Guthrie; Paul G Horgan; Donald C McMillan
Journal:  PLoS One       Date:  2012-08-03       Impact factor: 3.240

8.  An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.

Authors:  M J Proctor; D S Morrison; D Talwar; S M Balmer; D S J O'Reilly; A K Foulis; P G Horgan; D C McMillan
Journal:  Br J Cancer       Date:  2011-01-25       Impact factor: 7.640

9.  PET/CT: will it change the way that we use CT in cancer imaging?

Authors:  Rodney J Hicks; Robert E Ware; Eddie W F Lau
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

10.  The Relationship between ECOG-PS, mGPS, BMI/WL Grade and Body Composition and Physical Function in Patients with Advanced Cancer.

Authors:  Ross D Dolan; Louise E Daly; Claribel Pl Simmons; Aoife M Ryan; Wei Mj Sim; Marie Fallon; Derek G Power; Andrew Wilcock; Matthew Maddocks; Michael I Bennett; Caroline Usborne; Barry J Laird; Donald C McMillan
Journal:  Cancers (Basel)       Date:  2020-05-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.